Compare · DGX vs FTRE
DGX vs FTRE
Side-by-side comparison of Quest Diagnostics Incorporated (DGX) and Fortrea Holdings Inc. (FTRE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DGX and FTRE operate in Medical Specialities (Health Care), so they compete in similar markets.
- DGX is the larger of the two at $21.33B, about 18.5x FTRE ($1.15B).
- Over the past year, DGX is up 8.2% and FTRE is up 94.4% - FTRE leads by 86.2 points.
- DGX has been more active in the news (16 items in the past 4 weeks vs 4 for FTRE).
- Both have 25 recent analyst ratings on file.
- Company
- Quest Diagnostics Incorporated
- Fortrea Holdings Inc.
- Price
- $192.67-0.94%
- $12.17+5.83%
- Market cap
- $21.33B
- $1.15B
- 1M return
- -2.57%
- +28.24%
- 1Y return
- +8.24%
- +94.41%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 16
- 4
- Recent ratings
- 25
- 25
Quest Diagnostics Incorporated
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Latest DGX
- Quest Diagnostics Incorporated filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form FWP filed by Quest Diagnostics Incorporated
- Quest Diagnostics Prices $500 Million of Senior Notes
- Executive Vice President & CFO Samad Sam was granted 108 shares, increasing direct ownership by 0.32% to 33,376 units (SEC Form 4)
- SVP for Diagnostic Services Plewman Patrick increased direct ownership by 0.32% to 15,247 units (SEC Form 4)
- Director Gregg Vicky B was granted 68 shares, increasing direct ownership by 0.40% to 17,172 units (SEC Form 4)
- Director Carter Robert B increased direct ownership by 0.26% to 2,711 units (SEC Form 4)
- Director Lassiter Wright Iii increased direct ownership by 0.07% to 9,063 units (SEC Form 4)
- SVP, Clinical Solutions Kuppusamy Karthik increased direct ownership by 0.29% to 13,490 units (SEC Form 4)
- SVP & Chief Commercial Officer Delaney Mark E increased direct ownership by 0.31% to 11,901 units (SEC Form 4)
Latest FTRE
- SEC Form DEFA14A filed by Fortrea Holdings Inc.
- SEC Form DEF 14A filed by Fortrea Holdings Inc.
- Fortrea Announces Date for First Quarter 2026 Financial Results and Conference Call
- Fortrea Unveils Fortrea Intelligent Technology™ to Help Sponsors and Sites Run Smarter, More Integrated Trials
- Amendment: SEC Form SCHEDULE 13G/A filed by Fortrea Holdings Inc.
- SEC Form 4 filed by Russell Erin L
- Chief Operating Officer Morais Mark A. sold $16,633 worth of shares (1,804 units at $9.22) and converted options into 4,284 shares, increasing direct ownership by 4% to 69,899 units (SEC Form 4)
- Chief Financial Officer Mcconnell Jill G. converted options into 4,284 shares and sold $16,633 worth of shares (1,804 units at $9.22), increasing direct ownership by 4% to 72,276 units (SEC Form 4)
- SEC Form 4 filed by Fortrea Holdings Inc.
- SEC Form 4 filed by Fortrea Holdings Inc.